NTLA vs PSNL: fair value comparison
Intellia Therapeutics, Inc. and Personalis, Inc. · Updated 2026-10-19
NTLA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. PSNL has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, NTLA currently ranks higher by quality score.
| NTLA | PSNL | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $11.42 | $15.65 |
| 12-month range | $8.04–$25.89 | $5.04–$18.38 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #191 of 301 Healthcare | #193 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | Contracting |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: NTLA fair value analysis · PSNL fair value analysis